| P2093 | author name string | Joyce A Cramer | |
| | Christine de la Loge | |
| | Simon Borghs | |
| | Yves Brabant | |
| P2860 | cites work | Assessing the reliability of clinical scales when the data have both nominal and ordinal features: proposed guidelines for neuropsychological assessments | Q30890174 |
| | The Chalfont Seizure Severity Scale | Q33589904 |
| | Identifying meaningful intra-individual change standards for health-related quality of life measures | Q33916167 |
| | Quantitative assessment of seizure severity for clinical trials: a review of approaches to seizure components | Q34156372 |
| | Assessing the severity of seizures and epilepsy: which scales are valid? | Q34191997 |
| | How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure | Q35079886 |
| | Clinically important change in quality of life in epilepsy. | Q35468261 |
| | Seizure severity in children with epilepsy: a parent-completed scale compared with clinical data | Q36850380 |
| | Sensitivity testing of the Seizure Severity Questionnaire (SSQ). | Q42630077 |
| | Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial | Q42638125 |
| | Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials | Q42797086 |
| | Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial | Q43173503 |
| | Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures | Q44761812 |
| | Quality of life improvement with conversion to lamotrigine monotherapy | Q44880530 |
| | Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial | Q46138712 |
| | Changes in seizure severity and quality of life in patients with refractory partial epilepsy | Q48340099 |
| | Seizure severity is associated with quality of life independent of seizure frequency | Q49060518 |
| | Defining clinically meaningful change in health-related quality of life. | Q52013966 |
| | The National Hospital Seizure Severity Scale: a further development of the Chalfont Seizure Severity Scale. | Q52304792 |
| | Changes in quality of life in epilepsy: how large must they be to be real? | Q53499442 |
| | Clinical significance: A statistical approach to defining meaningful change in psychotherapy research | Q64386616 |
| | The development of a seizure severity scale as an outcome measure in epilepsy | Q67940149 |
| | A method of quantification for the evaluation of antiepileptic drug therapy | Q71228494 |
| | Development of a new seizure severity questionnaire: initial reliability and validity testing | Q77794013 |
| P921 | main subject | questionnaire | Q747810 |
| | seizure | Q6279182 |
| P304 | page(s) | 286-290 | |
| P577 | publication date | 2013-10-16 | |
| P1433 | published in | Epilepsy Behavior | Q15746410 |
| P1476 | title | Determining minimally important change thresholds for the Seizure Severity Questionnaire (SSQ). | |
| P478 | volume | 31 | |